Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth R Hess

Showing results (161-170 of 217) with videos related to

Pageof 22
Sort By:
Cancer|November 17, 2011
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic gliomaPierre Giglio, Megha Dhamne, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2010
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancerAdel Tabchy, Vicente Valero, Tatiana Vidaurre, et al.
Journal of Medical Internet Research|March 15, 2019
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational StudyGoldy C George, Eucharia C Iwuanyanwu, Adrianna S Buford, et al.
Cancer|September 5, 2002
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomasFunda Meric, Kenneth R Hess, Datla G K Varma, et al.
Neuro-Oncology|February 11, 2004
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium studyMichael D Prados, W K Alfred Yung, Howard A Fine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancerRoman Rouzier, Lajos Pusztai, Suzette Delaloge, et al.
Oncotarget|October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trialsRabih Said, Yang Ye, Gerald Steven Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancerKenneth R Hess, Keith Anderson, W Fraser Symmans, et al.
Journal of Translational Medicine|February 11, 2016
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cellsTakashi Shingu, Lindsay Holmes, Verlene Henry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
Pageof 22

Showing results (161-170 of 217) with videos related to

Sort By:
Pageof 22
Cancer|November 17, 2011
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic gliomaPierre Giglio, Megha Dhamne, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2010
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancerAdel Tabchy, Vicente Valero, Tatiana Vidaurre, et al.
Journal of Medical Internet Research|March 15, 2019
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational StudyGoldy C George, Eucharia C Iwuanyanwu, Adrianna S Buford, et al.
Cancer|September 5, 2002
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomasFunda Meric, Kenneth R Hess, Datla G K Varma, et al.
Neuro-Oncology|February 11, 2004
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium studyMichael D Prados, W K Alfred Yung, Howard A Fine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancerRoman Rouzier, Lajos Pusztai, Suzette Delaloge, et al.
Oncotarget|October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trialsRabih Said, Yang Ye, Gerald Steven Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancerKenneth R Hess, Keith Anderson, W Fraser Symmans, et al.
Journal of Translational Medicine|February 11, 2016
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cellsTakashi Shingu, Lindsay Holmes, Verlene Henry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
Pageof 22